- Home
- PROK vs EDD Comparison
PROK vs EDD Comparison
Compare PROK & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- EDD
- Stock Information
- Founded
- PROK 2015
- EDD 2007
- Country
- PROK United States
- EDD United States
- Employees
- PROK N/A
- EDD N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- EDD Finance Companies
- Sector
- PROK Health Care
- EDD Finance
- Exchange
- PROK Nasdaq
- EDD Nasdaq
- Market Cap
- PROK 271.2M
- EDD 326.0M
- IPO Year
- PROK N/A
- EDD N/A
- Fundamental
- Price
- PROK $2.33
- EDD $4.91
- Analyst Decision
- PROK Buy
- EDD
- Analyst Count
- PROK 3
- EDD 0
- Target Price
- PROK $4.00
- EDD N/A
- AVG Volume (30 Days)
- PROK 372.7K
- EDD 254.3K
- Earning Date
- PROK 08-09-2024
- EDD 01-01-0001
- Dividend Yield
- PROK N/A
- EDD 7.52%
- EPS Growth
- PROK N/A
- EDD N/A
- EPS
- PROK N/A
- EDD N/A
- Revenue
- PROK N/A
- EDD N/A
- Revenue This Year
- PROK N/A
- EDD N/A
- Revenue Next Year
- PROK N/A
- EDD N/A
- P/E Ratio
- PROK N/A
- EDD N/A
- Revenue Growth
- PROK N/A
- EDD N/A
- 52 Week Low
- PROK $1.12
- EDD $4.22
- 52 Week High
- PROK $8.56
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- PROK 51.06
- EDD 48.45
- Support Level
- PROK $2.07
- EDD $4.93
- Resistance Level
- PROK $2.45
- EDD $4.96
- Average True Range (ATR)
- PROK 0.17
- EDD 0.05
- MACD
- PROK 0.01
- EDD -0.02
- Stochastic Oscillator
- PROK 68.42
- EDD 11.76
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.